How does ARIAD's Ponatinib (Iclusig) Work

Mechanism of Action Series: Ponatinib

Ariad Pharmaceuticals' leukemia drug ponatinib has been in the news lately for major toxicity fears that can potentially derail its further clinical development. While these issues will be sorted out in coming months, it's a good time to review how does this drug work.

Ponatinib is a pan-inhibitor of native and T315I mutant forms of BCR-ABL kinase.